- UAA Congress 2025

Back

Final Presentation Format

Podium Abstract

Eposter Presentation

Eposter in PDF Format

Accept format: PDF. The file size should not be more than 5MB

Eposter in Image Format

Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB

Abstract

Abstract Title

Papillary renal neoplasm with reverse polarity—comparative study with CCPRCC, OPRCC, and PRCC1

Presentation Type

Podium Abstract

Manuscript Type

Clinical Research

Abstract Category *

Oncology: Kidney (non-UTUC)

Author's Information

Number of Authors (including submitting/presenting author) *

No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.

Co-author 1

tao wang pekinguwt0919@126.com beijing friendship hospital urology beijing China *

Co-author 2

yinong niu xiehonglan605@yeah.net beijing friendship hospital urology beijing China

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Co-author 16

Co-author 17

Co-author 18

Co-author 19

Co-author 20

Abstract Content

Introduction

Papillary renal neoplasm with reverse polarity (PRNRP) is a newly defined entity with distinct histomorphology and recurrent KRAS mutation. In this study, we aimed to identify and analyze the clinicopathological, immunohistochemical (IHC), and molecular features of PRNRP in our center and to evaluate its differential diagnosis with other tumors with which it is easily confused: clear cell papillary renal cell carcinoma (CCPRCC), oncocytic papillary renal cell carcinoma (OPRCC), and papillary renal cell carcinoma type 1 (PRCC1).

Materials and Methods

Nephrectomy specimens of PRNRP (n = 15), CCPRCC (n = 11), and OPRCC (n = 12) were retrieved from our pathology archives. We also selected typical cases of PRCC1 (n = 15) as a control group.

Results

PRNRP accounted for 3.05% (15/492) of all PRCC cases at our center. The median follow-up period was 41.3 months. All PRNRP cases were pT1N0M0, and only one involved recurrence (1 year after surgery). IHC analysis showed diffuse staining of CK7, EMA, and GATA3 but weak or negative staining of CD10, CD117, p504s, and vimentin in the PRNRP samples and distinctive IHC features in the other three tumor types. KRAS mutation was detected in 4/10 PRNRP cases. Among the 40 most commonly mutated genes identified, 5 (BCLAF1, PDE4DIP, NCOR1, PARP4, and PABPC1) have actionable alterations.

Conclusions

Our study supports the suggestion that PRNRP is an entity distinct from CCPRCC, OPRCC, and PRCC1.

Keywords

Papillary renal neoplasm with reverse polarity;Papillary renal cell carcinoma type 1;Clear cell papillary renal cell carcinoma;Oncocytic papillary renal cell carcinoma; Whole exon sequencing; KRAS

Figure 1

https://storage.unitedwebnetwork.com/files/1237/ab3a7fd4d28aee56093015bb380ad193.jpg

Figure 1 Caption

The cancer gene landscape of PRNRP patients.

Figure 2

https://storage.unitedwebnetwork.com/files/1237/d3d5273d49abeebace33615e20d586fa.jpg

Figure 2 Caption

Histological features of papillary renal neoplasm with reverse polarity.

Figure 3

https://storage.unitedwebnetwork.com/files/1237/9f408e92ee340d79b344033c79e6e335.png

Figure 3 Caption

Minorl structure changes of papillary renal neoplasm with reverse polarity.

Figure 4

https://storage.unitedwebnetwork.com/files/1237/94c27327e942f35281b7f3457c87c899.jpeg

Figure 4 Caption

IHC features of papillary renal neoplasm with reverse polarity.

Figure 5

https://storage.unitedwebnetwork.com/files/1237/b8ae881387acd485b8109a01508ff9a6.jpeg

Figure 5 Caption

IHC features of PRCC1, OPRCC, CCPRCC.

Presentation Order